FDA committee votes in favor of Darzalex Faspro for HR-SMM
A U.S. Food and Drug Administration (FDA) committee has voted in favor of Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat high-risk smoldering multiple myeloma…
News
Geneseeq’s new blood test may detect early-stage pancreatic cancer
Geneseeq Technology is developing a blood test that uses cell-free DNA (cfDNA) and artificial intelligence (AI) to detect early-stage pancreatic ductal adenocarcinoma — the…
BCB-276 cell therapy for pediatric brain cancer gets new FDA status
BCB-276, an experimental cell therapy that Brainchild Bio is developing for diffuse intrinsic pontine glioma (DIPG), has been named a regenerative medicine advanced…
Pembrolizumab improves survival outcomes in ovarian cancer trial
Treatment with pembrolizumab — an immune-modulating therapy sold for some cancers under the brand name Keytruda — improved survival among people with platinum-resistant ovarian cancer…
Cell therapy anito-cel extends treatment-resistant RRMM survival
Nearly all the people with relapsed or refractory multiple myeloma (RRMM) who took part in a Phase 2 clinical trial responded to the cell…
ELVN-001 shows cancer-killing potential in Phase 1 CML study
ELVN-001, an experimental treatment for chronic myeloid leukemia (CML), a type of blood cancer, is showing promising proof-of-concept effects for killing cancer cells in patients…
Adding elraglusib seen to improve survival in pancreatic cancer trial
Adding the experimental therapy elraglusib to standard chemotherapy led to statistically significant improvements in survival for people with metastatic pancreatic ductal adenocarcinoma (PDAC), a form…
New partners to help develop CAR T-cell therapy for brain cancer
Optieum Biotechnologies and Genezen are teaming up to help develop OPTF01, an experimental cell therapy for glioblastoma, an aggressive form of glioma.
Testosterone in gender-affirming care doesn’t raise cancer risk
The use of testosterone as part of gender-affirming care does not increase the risk of gynecological cancers in transgender men or gender-diverse people, a study…
IGI’s relapsed/refractory multiple myeloma drug wins fast track status
The U.S. Food and Drug Administration (FDA) has granted fast track status to ISB 2001, an experimental therapy for difficult-to-treat multiple myeloma. The designation…
